Aditya Bardia, MD, breast medical oncologist at Massachusetts General Hospital, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss antibody-drug conjugates.

Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Saba Shaikh, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss the DESTINY-Breast08 trial.

Nolan Priedigkeit, MD, PhD, medical oncology fellow at Dana-Farber Cancer Institute, and Andrew Brenner, MD, professor of medicine and breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss fusion RNAs and metastatic breast cancer.

Carey Anders, MD, medical director of Duke Brain and Spine Metastases Program, and Andrew Brenner, MD, professor of medicine and breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss what’s new for the treatment for CNS disease in metastatic breast cancer.

Seema Khan, MD, professor of breast surgical oncology at Northwestern Medicine, and Carissia Calvo-Strube, MD, FACS, assistant professor of breast surgical oncology at Mays Cancer Center at UT Health San Antonio, discuss optimizing local therapy for ductal carcinoma in situ: 5-year clinical outcomes of ECOG-ACRIN 4112.

Janet Dunn, PhD, head of cancer trials at Warwick Clinical Trials at Warwick Medical School, and Carissia Calvo-Strube, MD, FACS, assistant professor of breast surgical oncology at Mays Cancer Center at UT Health San Antonio, discuss the results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography.

Jack Cuzick, PhD, FRS, FMedSci, FRCP, professor of epidemiology at Queen Mary University of London, reflects on his career in conversation with SABCS Co-Director Virginia Kaklamani, MD.

Sherene Loi, MBBS, FRACP, PhD, FAHMS, head of translational breast cancer genomics and therapeutics lab at the University of Melbourne, and Virginia Kaklamani, MD, leader of the breast medical oncology program at Mays Cancer Center at UT Health San Antonio, discuss the options of treating ER positive breast with immunotherapy.

Hatem Azim, MD, chief medical officer at Emergence Therapeutics, and Marcela Mazo Canola, MD, breast medical oncologist at Mays Cancer Center at UT Health San Antonio, discuss if patients can interrupt endocrine therapy to attempt pregnancy.

Anne May, PhD, professor of clinical epidemiology of cancer survivorship at UMC Utrecht, and Lindsay Peterson, MD, MSCR, assistant professor of medicine for division of oncology at Cancer and Aging Research Group, discuss the effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer.